

Information Regarding Clinical Trial

Title	Phase 2, exploratory study of Nivolumab in combination with Ipilimumab in Subjects with Treatment-Naïve Stage IV or recurrent NSCLC
Protocol Number	CA209592
Sponsor	Bristol Meyer Squibb
Investigator	J. Thaddeus Beck, MD 3232 N. North Hills Blvd. Fayetteville, AR 72703
Study Related Phone Numbers	479-587-1700 (24 hours)
Key Points for Study	Prior adj. or neoadj. Chemo/radiation OK if occurred at least 6 months prior to enrollment. Must submit tissue block for PD-L1 IHC testing during screening. ECOG 0-1 2 cohorts: PD-L1 positive and negative, each receiving Nivolumab and Ipilimumab. Excluded: Known EGFR/ALK mutations, untreated CNS mets, prior tx with anti-PD-1, PD-L1, PD-L2, or CTLA-4